DT389-YP7, a Recombinant Immunotoxin against Glypican-3 That Inhibits Hepatocellular Cancer Cells: An In Vitro Study

Area of Science:

• Oncology
• Molecular Biology
• Immunotherapy

Background:

• Hepatocellular carcinoma (HCC) is a highly metastatic cancer with limited effective treatments.
• Developing targeted therapies is crucial to improve efficacy and minimize side effects.
• Immunotoxins (ITs) offer a promising approach by selectively targeting cancer cells for destruction.

Purpose of the Study:

• To design and evaluate a novel immunotoxin targeting the Glypican-3 (GPC3) oncofetal antigen on HCC cells.
• To assess the specificity and cytotoxic effects of the GPC3-targeted immunotoxin on HCC cell lines.

Main Methods:

• A recombinant immunotoxin was constructed by fusing a truncated diphtheria toxin (DT389) with a humanized YP7 single-chain variable fragment (scFv) targeting GPC3.
• Cytotoxic effects were evaluated on GPC3-positive (HepG2) and GPC3-negative (SkBr3) cell lines.
• Assays included cell viability (IC50), morphology changes, cell cycle analysis, reactive oxygen species (ROS) production, and apoptosis/necrosis induction.

Main Results:

• The immunotoxin demonstrated specific binding to GPC3-positive HepG2 cells with a dissociation constant (Kd) of 11.39 nM.
• Treatment with the immunotoxin significantly reduced HepG2 cell viability (IC50 = 848.2 ng/mL), induced morphological changes, G2 cell cycle arrest, increased ROS, and promoted apoptosis/necrosis.
• No significant toxic effects were observed on GPC3-negative SkBr3 cells, confirming target specificity.

Conclusions:

• The novel GPC3-targeted immunotoxin exhibits potent and specific cytotoxic activity against HCC cells in vitro.
• This GPC3-targeted immunotoxin represents a potential therapeutic candidate for hepatocellular carcinoma.
• Further preclinical and clinical studies are warranted to validate its therapeutic potential.